The addition of stereotactic body radiation therapy (SBRT) to ipilimumab (Yervoy) and nivolumab (Opdivo) did not confer improved progression-free survival (PFS) vs the immunotherapy combination alone among patients with advanced renal cell carcinoma (RCC), according to findings from the phase 2 CYTOSHRINK trial (NCT0490710) presented at the
Specifically, among patients treated in the intent-to-treat population, the median PFS was 10.2 months (95% CI, 5.1-18.1) in the control arm (n = 24) vs 6.3 months (95% CI, 3.9-11.7) in the SBRT arm. Moreover, the 12-month PFS rates among patients treated in each arm were 47.8% (95% CI, 26.8%-66.1%) vs 34.9% (95% CI, 21.2%-48.9%), respectively (HR, 1.20; 95% CI, 0.65-2.21; P = .56).
A per protocol (PP) analysis showed that among patients…